We are monitoring the impact of COVID-19 on North America Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1120
Share on
Share on

North America Monoclonal Antibodies Market Research Report – Segmented By Source, Indication, End-User, Application, Country (US, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1120
Pages: 179

North America Monoclonal Antibodies Market Size (2021 to 2026)

The size of the Monoclonal Antibodies Market in North America was worth USD 14.99 Billion in 2021 and is estimated to grow at a CAGR of 6.24%, to reach USD 20.29 Billion by 2026.

Monoclonal antibodies have the potential to recognize and destroy unhealthy cells immediately, suppress cancer cell proliferation, and distribute radioactive particles or chemo medications to individual cells, reducing the risk of medication-related side effects while also improving immune system activity. Antibody vaccines have a greater success rate in inducing the desired medication, leading to the production of monoclonal antibodies (mAbs), which attack a particular region or cell. The monoclonal antibodies market in North America is further growth due to the increasing availability of cost-effective biosimilar monoclonal antibodies. Also, the rising prevalence of cancer is projected to raise demand for infusion therapies, leading to the monoclonal antibody market's substantial rise. The rapidly increasing number of cancers across North America is showing market growth.

Over the projected period, increasing research partnerships to construct a comprehensive drug pipeline is expected to be a major factor driving market growth. However, the market is likely to expand as the number of product approvals rises. In addition, the prevalence of cancer, autoimmune disorders, respiratory diseases, allergic diseases, and microbial diseases are all on the rise, resulting in a surge in demand for mAb therapy. The market is expected to expand due to a growing number of government programs and support for clinical trials of medicines used in the Covid-19 treatment. The Food and Drug Administration (FDA) is a government agency under the U.S. Department of Health and Human Services that oversees the monoclonal antibody and prescription drug markets. However, in recent years, the monoclonal antibody industry has seen several commercial strategies. Top firms in the industry strategically purchase start-ups and mid-sized businesses to expand their product and service offerings. Furthermore, the monoclonal antibody therapeutics market is estimated to grow due to increased product launches and regulatory funding to treat rare diseases by the USFDA.

Alternative therapy options and alternative therapies are becoming more common worldwide, which is expected to have a negative impact on the market for monoclonal antibody drugs. Homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy treatments are gaining acceptance and gradually replacing conventional hospital procedures. 

This research report on the North American Monoclonal Antibodies Market has been segmented & sub-segmented into the following categories:

By Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

By Indication:

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Other)

By End-User: 

  • Hospitals/Clinics
  • Research Institute
  • Diagnostic Laboratories

By Application: 

  • Medical
  • Experimental
  • Western Blot
    • ELISA
    • Radioimmune Assays
    • Immunofluorescence
    • Others

By Country: 

  • The U.S.
  • Canada
  • Rest of North America

Geographically, the North America mAB’s market dominated the global monoclonal antibodies market in 2020. The market growth in the region is attributed to the presence of advanced healthcare infrastructure and technological advancements in the healthcare sector. North America has the fastest-growing regional market due to the emergence of leading biopharmaceutical players. The major contributors in the region are the United States and Canada. 

In the North American regional market, The United States monoclonal antibodies market accounted for the highest share of the monoclonal antibodies market in 2020. the United States is the largest market for mAb’s, while Canada is estimated to be the fastest-growing due to growing awareness about antibody products. The mAbs market in the United States would benefit from rising demand influenced by medical-technological advances. The Food and Drug Administration (FDA) is an American government department that oversees the monoclonal antibody and prescription drug industries. It is a division of the Department of Health and Human Services in the United States. Furthermore, the number of coronavirus cases increases the need for particular therapeutic options, resulting in the growth of mono-specific antibodies, which will help the U.S. monoclonal antibody market expand significantly in the coming year.

On the other hand, the Canadian monoclonal antibodies market is projected to contribute to the North American regional market growth. 

KEY MARKET PARTICIPANTS:

Some of the major companies dominating the market by their products include GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., and Biogen Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Seattle Genetics (U.S.)                          

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.9 Biogen Inc.(U.S.)                      

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  2. North America Chimeric Market By Region, From 2021 to 2026 ( USD Billion )
  3. North America Humanized Market By Region, From 2021 to 2026 ( USD Billion )
  4. North America Human Market By Region, From 2021 to 2026 ( USD Billion )
  5. North America Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  6. North America Autoimmune Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  7. North America Infectious Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  8. North America Cardiovascular Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  9. North America CNS Disorders Market By Region, From 2021 to 2026 ( USD Billion )
  10. North America Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2021 to 2026 ( USD Billion )
  11. North America Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  12. North America Research Institute Market By Region, From 2021 to 2026 ( USD Billion )
  13. North America Diagnostic Laboratories Market By Region, From 2021 to 2026 ( USD Billion )
  14. North America Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  15. North America Experimental Market By Region, From 2021 to 2026 ( USD Billion )
  16. United States Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  17. United States Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  18. United States Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  19. United States Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  20. Canada Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  21. Canada Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  22. Canada Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  23. Canada Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  24. North America Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  25. North America Breast Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  26. North America Colorectal Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  27. North America Lung Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  28. North America Pancreatic Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  29. North America Others Market By Region, From 2021 to 2026 ( USD Billion )
  30. United States Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  31. Canada Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  32. North America Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )
  33. North America ELISA Market By Region, From 2021 to 2026 ( USD Billion )
  34. North America Radioimmune Assays Market By Region, From 2021 to 2026 ( USD Billion )
  35. North America Immunofluorescence Market By Region, From 2021 to 2026 ( USD Billion )
  36. North America Others Market By Region, From 2021 to 2026 ( USD Billion )
  37. United States Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )
  38. Canada Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample